Beam Therapeutics
7.07 %
-24.99 %
Yet to be announced
Company Overview
Beam Therapeutics Inc. is a biotechnology company focused on developing precision genetic medicines through its proprietary base editing technology. The company aims to treat serious diseases by precisely targeting and editing the genes associated with these conditions. Their technology allows them to make highly specific edits to DNA bases without cutting the DNA strand, potentially offering more precise genetic modifications with fewer unwanted effects than traditional gene editing approaches.
The company is currently in the research and development phase, working on various programs targeting conditions in areas including hematology, oncology, and genetic diseases. As a pre-commercial stage company, Beam's primary activities involve research, development, and advancing their therapeutic candidates through clinical trials.
Revenue Sources
PassBeam Therapeutics is a pre-commercial biotechnology company focused on developing genetic medicines. Their revenue primarily comes from collaboration agreements and research partnerships. Based on the available financial data and SEC filings, there is no indication that the company derives any revenue from haram sources. The company's business model and revenue streams are focused on legitimate medical research and development activities.
Reliance on Interest
| Reporting Date | Total Revenue | Total Expense | Interest Income | Interest Expense | Interest Income Ratio | Interest Expense Ratio |
|---|---|---|---|---|---|---|
| March 31, 2025 | $7.47m | $116.92m | - | $-9,900,000.0 | 0.00% | 8.44% |
| Dec. 31, 2024 | $30.07m | $119.18m | - | $-11,000,000.0 | 0.00% | 9.17% |
| Sept. 30, 2024 | $14.27m | $108.65m | - | $-12,000,000.0 | 0.00% | 11.16% |
| June 30, 2024 | $11.77m | $102.48m | - | $-14,000,000.0 | 0.00% | 13.85% |
As Beam Therapeutics is still in its pre-commercial research and development phase, we will skip the interest ratios check. The company has not yet reached its mature operational stage that would reflect its normal, intended business activities. The current financial profile shows significant R&D expenses and limited revenue from collaborations, which is typical for early-stage biotech companies.
Operational Ethics
PassBased on thorough review of the company's operations, locations, and partnerships through SEC filings and public information, there is no evidence of significant associations with entities involved in human rights violations. The company's primary operations are based in the United States, and there are no documented ongoing partnerships or operations with the state of Israel or direct involvement with the Chinese Communist Party.
Comments